Clinical outcomes and radiation pneumonitis after concurrent EGFR ‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer

ConclusionsCombined EGFR ‐TKI and radiotherapy showed favorable survival inEGFR‐mutant patients with inoperable stage III NSCLC, with a 6.7% incidence of grade 3 radiation pneumonitis/pneumonitis, despite a higher incidence of mild‐to‐moderate radiation pneumonitis.Key pointsSignificant findings of the studyWe evaluated the outcomes and radiation pneumonitis after EGFR ‐TKI during interval radiotherapy. EGFR‐TKI plus radiotherapy increased survival in patients withEGFR‐mutant inoperable stage III NSCLC. The mild‐to‐moderate radiation pneumonitis incidence increased but no grade 4–‐5 adverse events occurred.What this study addsThe combination of EGFR ‐TKI and radiotherapy might carry a risk of pneumonitis; however, there are limited data concerning dose constraints. Our results showed a slightly higher incidence of mild or moderate radiation pneumonitis by strict dose limitation.

Source: Thoracic Cancer - March 12, 2021 Category: Cancer & Oncology Authors: Kunpeng Xu, Jun Liang, Tao Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lu, Xin Wang, Lei Deng, Wenyang Liu, Jianyang Wang, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang Tags: ORIGINAL ARTICLE Source Type: research